Investigation of controlled salmeterol xinafoate and fluticasone propionate release from double molecular imprinted nanoparticles

• DOI: 10.1007/s00289-024-05299-6
• Publication Date: 2024-05-14T19:01:53Z
• Authors: Esra Feyzioğlu-Demir; Sinan Akgöl
• Keywords: Fluticasone propionate; Molecularly imprinted polymer; Thermosetting polymer

Abstract Salmeterol xinafoate (SAM) and fluticasone propionate (FLU) are one of the drug combinations used together in treatment lung diseases such as asthma chronic obstructive pulmonary disease (COPD). The aim this study is to investigate usability novel dual molecular imprinted nanoparticles (poly(2-hydroxyethyl methacrylate-N-methacryloyl-(L)-alanine-N-methacryloyl-(L)-histidine) [p(HEMA-MAAL-MAH)], abbr. DMIPNPs) a controlled release systems. In study, SAM FLU drugs were chosen model because they these diseases. DMIPNPs prepared by surfactant-free emulsion polymerization method characterized scanning electron microscopy (SEM) fourier transform infrared spectrometer (FTIR). vitro experiments, conditions optimized. from experiments also performed simulated fluid (SLF). amount released found 4.79 5.68 mg/g SLF medium at end 48 h, respectively. kinetics calculated medium. was determined be compatible with Higuchi models. According results, DMIPNPs, dual-template monomers, promising materials that can two different drugs. Graphical abstract